首页 | 本学科首页   官方微博 | 高级检索  
检索        

氧化苦参碱防治半乳糖胺诱导大鼠肝纤维化的实验研究
引用本文:杨文卓,曾民德,范竹萍,茅益民,宋育林,贾一韬,陆伦根,陈成伟,彭延申,朱红音.氧化苦参碱防治半乳糖胺诱导大鼠肝纤维化的实验研究[J].中华肝脏病杂志,2002,10(3):193-196.
作者姓名:杨文卓  曾民德  范竹萍  茅益民  宋育林  贾一韬  陆伦根  陈成伟  彭延申  朱红音
作者单位:1. 200001,上海第二医科大学附属仁济医院消化疾病研究所
2. 上海市闸北区中心医院
3. 南京军区八五医院肝病研究中心
基金项目:上海市卫生局重大发展基金(99ZDI001)
摘    要:目的 观察氧化苫参碱(oxymatrine,OM)预防及治疗大鼠肝纤维化的疗效并探讨其作用机制。方法 采用半乳糖胺诱导的大鼠肝纤维化模型,观察OM(90mg/kg)干预前后血及肝组织生物化学、羟脯氨酸含量、TGF β_1 mRNA表达水平及病理组织学改变。结果 OM干预组肝组织羟脯氨酸含量 (μg/mg)较模型组显著下降(预防观察组为0.50±0.11和0.99±0.14,t=8.366,P<0.01;治疗观察组为0.44±0.04和0.70±0.06,t=9.839,P<0.01);与模型组比较,干预组血清ALT、AST亦显著下降(P<0.01);病理组织学显示干预组较模型组 Ⅰ、Ⅲ型胶原沉积减少,纤维间隔纤细,数量减少;干预织肝组织匀浆内超氧化物歧化酶活性(NU/mg)较模型组升高(预防观察组为149.81±15.28和95.22±16.33,t=7.309,P<0.01;治疗观察组为157.68±19.54和119.88±14.94,t=4.348,P<0.01), 而丙二醛(nmol/mg)低于模型组(预防观察组为2.06±0.17和4.57±0.37,t=17.529,P<0.01;治疗观察组为1.76±0.24和3.10±0.17,t=12.697,P<0.01);PT-PCR显示干预组TGF β_1 mRNA表达水平降低(预防观察组为0.21±0.01和0.50±0.01,t-48.665,P<0.01;治疗观察组为0.18±0.02和0.38±0.01,t=22.464,P<0.01)。结论 氧化苫参碱对半乳糖胺诱导的肝纤维化有预防及治疗作用,其部分机制为通过

关 键 词:肝纤维化  半乳糖胺  受体  转化生长因子β  氧化苦参碱  OM  治疗  预防  动物模型
修稿时间:2001年9月30日

Prophylactic and therapeutic effect of oxymatrine on D-galactosamine-induced rat liver fibrosis
YANG Wenzhuo,ZENG Minde,FAN Zhuping,MAO Yimin,SONG Yulin,JIA Yitao,LU Lungen,CHEN Chengwei,PENG Yanshen and ZHUHongyin,Shanghai Digestive Disease Institute,Renji Hospital,Shanghai l,China.Prophylactic and therapeutic effect of oxymatrine on D-galactosamine-induced rat liver fibrosis[J].Chinese Journal of Hepatology,2002,10(3):193-196.
Authors:YANG Wenzhuo  ZENG Minde  FAN Zhuping  MAO Yimin  SONG Yulin  JIA Yitao  LU Lungen  CHEN Chengwei  PENG Yanshen and ZHUHongyin  Shanghai Digestive Disease Institute  Renji Hospital  Shanghai l  China
Institution:Shanghai Digestive Disease Institute, Renji Hospital, Shanghai 200001, China.
Abstract:OBJECTIVE: To investigate the prophylactic and therapeutic effect of oxymatrine on experimental liver fibrosis and to reveal its mechanism. METHODS: By establishing D-galactosamine-induced rat liver fibrosis model, we observed the effect of oxymatrine on serum and tissue biochemical indexes, content of liver hydroxyline, expression of TGF?1 mRNA and changes of tissue pathology. RESULTS: There was a decline of liver hydroxyline and serum AST and ALT in oxymatrine group compared to those of the D-GalN group. The hydroxyline content in oxymatrine pretreatment group was (0.50 0.11)mug/mg compared with (0.99 0.14)mug/mg in D-GalN group (t=8.366, P<0.01). The content in oxymatrine treatment group was (0.44 0.04)mug/mg compared with 0.70 0.06 in D-GalN group (t=9.839, P<0.01). The SOD activity was (149.81 15.28) NU/mg in oxymatrine pretreatment group and (95.22 16.33) NU/mg in the model group (t=7.309, P<0.01); (157.68 19.54) NU/mg in the treatment group compared with (119.88 14.94) NU/mg in the model group (t=4.348, P<0.01). MDA in the pretreatment group was (2.06 0.17) nmol/mg, lower than (4.57 0.37) nmol/mg in the model group (t=17.529, P<0.01). In the treatment group, it was (1.76 0.24)nmol/mg, lower than (3.10 0.17) nmol/mg in the model group (t=12.697, P<0.01). TGF?1 mRNA reduced in the pretreatment and treatment groups as compared with that in the model group (0.21 0.01 vs 0.50 0.01, t=48.665, P<0.01; 0.18 0.02 vs 0.38 0.01, t=22.464, P<0.01). Electron microscopy showed that oxymatrine group had milder hepatocyte degeneration and less fibrosis accumulation than did the model group. Microscopy revealed wide septa expansion from the portal area to the central venous, piecemeal and confluent necrosis and pseudo-nodular formation in part of the lobular in the model group. While in oxymatrine group these lesions were much improved. CONCLUSIONS: Oxymatrine shows prophylactic and therapeutic effect in D-galactosamine induced rat liver fibrosis. This is partly by protecting hepatocyte and suppressing fibrosis accumulation through anti-lipoperoxidation.
Keywords:Liver cirrhosis  D-galactosamine  Receptor  transforming growth factor beta  Rats  Oxymatrine
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号